uniQure NV Dossier
Qualitative Analysis
Business overview
uniQure N.V. (NASDAQ: QURE) is a pioneering clinical-stage biotechnology company focused on the development of innovative gene therapies designed to treat severe genetic and neurodegenerative disorders. The company's proprietary platform leverages adeno-associated virus (AAV) vectors to deliver therapeutic genetic material directly to target tissues. uniQure's lead investigational program is AMT-130, a one-time administered gene therapy designed to silence the huntingtin gene using artificial microRNAs to treat Huntington's disease. Beyond Huntington's disease, uniQure is advancing a robust pipeline targeting temporal lobe epilepsy (AMT-260), Fabry disease (AMT-191), and amyotrophic lateral sclerosis (ALS). The company also receives royalty streams from HEMGENIX, a gene therapy for hemophilia B commercialized by CSL Behring.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following a constructive Type B meeting with the FDA in June 2026, uniQure is pivoting its regulatory strategy to submit a BLA for accelerated approval of AMT-130 in Huntington's disease in Q3 2026, utilizing 3-year Phase I/II data as the primary basis.
Expected impact: Accelerates the potential commercial launch of the first genetic treatment for Huntington's disease.
Discontinuation of the AMT-162 program for SOD1-ALS following a safety review and dose-limiting toxicity in the EPISOD1 trial, allowing the company to focus capital and R&D efforts on higher-value programs like AMT-130, AMT-260, and AMT-191.
Expected impact: Reduces R&D expenses and extends the company's cash runway into the second half of 2029.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
In April 2026, uniQure entered into agreements with CSL Behring and Genezen to terminate its remaining HEMGENIX supply obligations and minimum purchase commitments. Genezen was designated as CSL Behring's direct contract manufacturing organization, fully transitioning manufacturing responsibilities away from uniQure.
Terms: Terminates uniQure's supply obligations and minimum purchase commitments after delivery of contractually specified batches in mid-2026. This transition has no impact on future royalties or milestones owed to uniQure under the original licensing agreement with CSL Behring.